Is IQV a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for IQVIA Holdings (IQV) rests on Record backlog and bookings momentum: IQVIA ended the first quarter of 2026 with a record backlog of about $34.2 billion, of which roughly $8.9 billion is convertible to revenue over the next twelve months, up nearly 8 percent year over year. Revenue (FY2025) is ~$16.3 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: IQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings. Whether IQV is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

IQVIA Holdings is a healthcare-focused data, analytics, and clinical-research company formed in 2016 from the merger of Quintiles (a large CRO) and IMS Health (a pharmaceutical-data provider). It operates in three segments: Technology & Analytics Solutions, which sells prescription and market data, real-world evidence, and commercial software to drug and device makers; Research & Development Solutions, its clinical research organization arm that designs and runs clinical trials on behalf of pharma and biotech sponsors; and Contract Sales & Medical Solutions. IQVIA makes money from long-duration trial contracts, recurring data and software subscriptions, and consulting, serving essentially all of the top 20 global pharmaceutical companies. The investment picture is that of a wide-moat compounder tied to the health of global drug development. IQVIA's edge comes from combining one of the industry's deepest proprietary data assets with the operational scale to run trials, which is hard for rivals to replicate. For full-year 2025 the company reported revenue of about $16.3 billion and adjusted diluted EPS of roughly $11.92, and it entered 2026 with a record R&D backlog of about $34.2 billion. Growth is real but cyclical: when biotech funding tightens or large pharma delays programs, trial bookings and RFP flow soften, and the company carries substantial debt that it refinances at higher rates. The bull case now leans heavily on IQVIA layering AI agents onto its data to widen margins.

What's the case for buying IQV?

1. Record backlog and bookings momentum.

IQVIA ended the first quarter of 2026 with a record backlog of about $34.2 billion, of which roughly $8.9 billion is convertible to revenue over the next twelve months, up nearly 8 percent year over year. Net new bookings in the CRO arm ran a 1.04x book-to-bill in the quarter and 1.11x on a trailing-twelve-month basis, a leading indicator that future revenue is being contracted faster than it is being recognized.

2. Proprietary data and analytics moat.

The Technology & Analytics Solutions segment, which grew in the low double digits recently, sells prescription data, real-world evidence, and commercial software that nearly every large drugmaker relies on. Because IQVIA owns the underlying datasets rather than licensing them, it can embed that data directly into its software and consulting, creating a recurring, higher-margin revenue base that is difficult for competitors to copy.

3. AI agents and margin expansion.

Management has deployed roughly 192 AI agents across 64 use cases, with 19 of the top 20 pharma companies actively using IQVIA agents in their workflows. By applying AI to trial design, patient recruitment, and commercial analytics, IQVIA aims to expand adjusted EBITDA margins while giving clients faster, cheaper development, turning its data scale into an efficiency advantage.

4. Bolt-on acquisitions extending reach.

In February 2026 IQVIA agreed to acquire drug-discovery assets from Charles River Laboratories, extending its laboratories capabilities earlier into the R&D value chain. Deals like this let IQVIA capture more early-stage biotech and pharma spend and broaden the range of services it can bundle to existing clients.

What are the risks to IQV?

IQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings. Large pharma patent cliffs, pricing pressure, and policy changes around drug spending can prompt clients to delay or cancel programs. The company also carries a substantial debt load that it refinances at higher coupons in a higher-for-longer rate environment, which pressures free cash flow and limits strategic flexibility. Competition from ICON and Labcorp in clinical research and Veeva Systems in commercial software is intensifying, and any misstep in converting the large backlog into recognized revenue would weigh on results.

How is IQV valued? (as of JULY 2026)

Price

$206.26

Market cap

$34.42B

P/E (TTM)

25.65

Forward P/E

14.56

Price / book

5.53

Beta

1.20

52-week range

$154.50 to $247.05

Snapshot for IQV as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (FY2025): ~$16.3 billion
Adjusted diluted EPS (FY2025): ~$11.92
Adjusted EBITDA (FY2025): ~$3.8 billion
Backlog (Q1 2026): ~$34.2 billion
2026 revenue guidance: ~$17.15 to $17.35 billion
Market cap: ~$35 billion

IQVIA reported full-year 2025 revenue of about $16.3 billion with adjusted diluted EPS near $11.92, and issued 2026 revenue guidance of roughly $17.15 to $17.35 billion alongside adjusted EPS guidance of about $12.55 to $12.85. At a mid-2026 share price near $208 and a market cap around $35 billion, the stock traded at a P/E in the high teens to about 20x, a valuation that has compressed from prior years. The record backlog of about $34.2 billion provides visibility, but the pace of backlog-to-revenue conversion and biotech funding trends drive how much of that guidance is realized.

How do you decide if IQV is a buy?

Rather than asking whether IQV is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold IQV indirectly through an index or sector ETF before adding more.

For the full picture, see the IQV stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about IQV against your real portfolio and see your actual exposure before deciding.

The bottom line on IQV

The bottom line: IQVIA Holdings's story right now is Record backlog and bookings momentum, with revenue (fy2025) at ~$16.3 billion. If you believe that narrative continues, the call is about sizing IQV sensibly and checking overlap with what you own; if you doubt it (the risk: iQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around IQV with Walnut

Use IQVIA Holdings as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is IQV a good stock to buy right now?

The case for IQVIA Holdings right now is Record backlog and bookings momentum, with revenue (fy2025) at ~$16.3 billion. If you believe that thesis holds, IQV is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is iQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does IQVIA Holdings do?

IQVIA Holdings is a healthcare-focused data, analytics, and clinical-research company formed in 2016 from the merger of Quintiles (a large CRO) and IMS Health (a pharmaceutical-dat

What are the main risks of IQV?

What does IQVIA do?

IQVIA is a healthcare data, analytics, and clinical-research company. It runs clinical trials for drugmakers through its contract research organization, and it sells prescription and market data, real-world evidence, and commercial software to pharmaceutical and life-sciences clients worldwide.

How do I invest in IQV?

IQV trades on the New York Stock Exchange, so you can buy shares or fractional shares through any major brokerage. It is also held in various healthcare and life-sciences ETFs, and can be added as one holding within a thematic basket alongside related companies.

Is IQVIA a CRO?

Yes. Its Research & Development Solutions segment is one of the largest contract research organizations in the world, designing and running clinical trials on behalf of pharma and biotech sponsors. IQVIA pairs that CRO business with a large healthcare-data and analytics operation.

How big is IQVIA's revenue?

IQVIA reported full-year 2025 revenue of about $16.3 billion. For 2026 the company guided to roughly $17.15 to $17.35 billion in revenue, implying mid-single-digit growth at the midpoint.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell IQV; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.